Sonde Health struck a deal with Qualcomm Technologies Inc. to embed its vocal health biomarker product, Sonde One, in the Snapdragon 888 and 778G 5G mobile platforms. The deal would make vocal biomarker monitoring native to the devices that use the company’s chips in mobile and IoT devices.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Airstrip, Avita Biomedical, Biointellisense, Exactech, International Isotopes, Invivo Therapeutics, Radqual, RTI Surgical, Seegene, Symphonyai.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Antengene, Bayer, Chemocentryx, Coya, Diurnal, Enochian, Gensight, Inotrem, Iveric, Janssen, Kintor, Prilenia, Provention, Seagen, Sigilon, Sirnaomics, Soleno, Tetra, Tevogen, Valneva.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alterola, Abti, Aridis, Astellas, Blue Water, Cellectar, Etherna, Evgen, Evrys, Excellthera, Exevir, Heat, Intocell, Legochem, Probiogen.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Carrot, Quidel, Ortho Clinical Diagnostics, Uvision360.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Bardy Diagnostics, Dariohealth, Hillrom, Histosonics, Tada Medical.
DUBLIN – Inotrem SA has received €45 million (US$53 million) in public funding commitments to move its Trem-1 inhibitor, nangibotide, into a phase II/III trial in COVID-19 patients who are critically ill and on ventilation.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Beigene, Bluebird, Humanigen, Innovent, Lysogene.
RSS
